JP7576779B2 - 抗体-stingアゴニスト複合体および免疫療法におけるそれらの使用 - Google Patents

抗体-stingアゴニスト複合体および免疫療法におけるそれらの使用 Download PDF

Info

Publication number
JP7576779B2
JP7576779B2 JP2022502910A JP2022502910A JP7576779B2 JP 7576779 B2 JP7576779 B2 JP 7576779B2 JP 2022502910 A JP2022502910 A JP 2022502910A JP 2022502910 A JP2022502910 A JP 2022502910A JP 7576779 B2 JP7576779 B2 JP 7576779B2
Authority
JP
Japan
Prior art keywords
cdn
alkyl
adc
formula
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022502910A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541517A (ja
JP2022541517A5 (cg-RX-API-DMAC7.html
Inventor
チェン、ジージエン
シー、へピン
ウェイ、チー
チェン、チュオ
サン、リジュン
チウ、ジエン
ウー、ユートン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of JP2022541517A publication Critical patent/JP2022541517A/ja
Publication of JP2022541517A5 publication Critical patent/JP2022541517A5/ja
Application granted granted Critical
Publication of JP7576779B2 publication Critical patent/JP7576779B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP2022502910A 2019-07-19 2020-07-20 抗体-stingアゴニスト複合体および免疫療法におけるそれらの使用 Active JP7576779B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962876590P 2019-07-19 2019-07-19
US62/876,590 2019-07-19
US202063019212P 2020-05-01 2020-05-01
US63/019,212 2020-05-01
PCT/US2020/042815 WO2021016204A1 (en) 2019-07-19 2020-07-20 Antibody-sting agonist conjugates and their use in immunotherapy

Publications (3)

Publication Number Publication Date
JP2022541517A JP2022541517A (ja) 2022-09-26
JP2022541517A5 JP2022541517A5 (cg-RX-API-DMAC7.html) 2023-07-26
JP7576779B2 true JP7576779B2 (ja) 2024-11-01

Family

ID=71995149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502910A Active JP7576779B2 (ja) 2019-07-19 2020-07-20 抗体-stingアゴニスト複合体および免疫療法におけるそれらの使用

Country Status (13)

Country Link
US (3) US11033635B2 (cg-RX-API-DMAC7.html)
EP (1) EP3999118A1 (cg-RX-API-DMAC7.html)
JP (1) JP7576779B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220054794A (cg-RX-API-DMAC7.html)
CN (2) CN117838878A (cg-RX-API-DMAC7.html)
AU (1) AU2020315802A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022000854A2 (cg-RX-API-DMAC7.html)
CA (1) CA3147890A1 (cg-RX-API-DMAC7.html)
IL (1) IL289866A (cg-RX-API-DMAC7.html)
MX (1) MX2022000815A (cg-RX-API-DMAC7.html)
TW (1) TWI877186B (cg-RX-API-DMAC7.html)
WO (1) WO2021016204A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202201988B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033635B2 (en) * 2019-07-19 2021-06-15 Immunesensor Therapeutics, Inc. Antibody-STING agonist conjugates and their use in immunotherapy
US20240218009A1 (en) * 2021-04-21 2024-07-04 Merck Sharp & Dohme Llc Novel forms of cyclic dinucleotide compounds
US20250057967A2 (en) * 2021-06-25 2025-02-20 Bolt Biotherapeutics, Inc. Bis-benzimidazole sting agonist immunoconjugates, and uses thereof
EP4412660A1 (en) * 2021-10-04 2024-08-14 Bolt Biotherapeutics, Inc. Asymmetric bis-benzimidazole sting agonist immunoconjugates and uses thereof
US20250108123A1 (en) * 2021-12-17 2025-04-03 Jacobio Pharmaceuticals Co., Ltd. Compound-linker constructs comprising novel compounds useful as sting agonists and uses thereof
EP4653017A1 (en) * 2023-01-18 2025-11-26 Tyligand Bioscience (Shanghai) Limited Antibody-drug conjugate and use thereof
IL322523A (en) * 2023-02-28 2025-10-01 Eisai R&D Man Co Ltd Anti-PSMA antibodies, conjugates and methods of use
CN122180515A (zh) * 2023-06-30 2026-06-09 免疫原公司 包含sting激动剂的组合物和用于治疗神经胶质瘤的使用方法
CN117343111B (zh) * 2023-12-04 2024-02-06 康羽生命科学技术(苏州)有限公司 核苷修饰物n2-异丁酰-2'-甲氧基鸟苷的制备方法
CN120204418A (zh) * 2023-12-27 2025-06-27 上海迪诺医药科技有限公司 环状二核苷酸化合物、其偶联物及应用
WO2026035986A1 (en) 2024-08-07 2026-02-12 Bighat Biosciences, Inc. Humanized anti-cdh17 antibodies and use of the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522914A (ja) 2015-08-13 2018-08-16 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Stingアゴニストとしての環状ジヌクレオチド化合物
WO2018200812A1 (en) 2017-04-28 2018-11-01 Novartis Ag Antibody conjugates comprising sting agonist
JP2019509339A (ja) 2016-03-18 2019-04-04 イミューン センサー リミテッド ライアビリティ カンパニー 環状ジヌクレオチド化合物および使用方法
WO2019129880A1 (en) 2017-12-29 2019-07-04 Invivogen Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
TR201808537T4 (tr) * 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
BR112014013526A8 (pt) 2011-12-05 2017-06-13 Igenica Biotherapeutics Inc conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
GB2552041A (en) * 2015-12-07 2018-01-10 Opi Vi - Ip Holdco Llc Compositions of antibody construct-agonist conjugates and methods thereof
US20170158772A1 (en) 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
DE212016000029U1 (de) 2015-12-07 2017-07-30 Opi Vi - Ip Holdco Llc Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
FI3922279T3 (fi) 2016-08-30 2025-02-04 Dana Farber Cancer Inst Inc Lääkkeenantokoostumuksia ja niiden käyttötapoja
WO2018100558A2 (en) * 2016-12-01 2018-06-07 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
RU2019122598A (ru) * 2016-12-20 2021-01-22 Мерк Шарп И Доум Корп. Циклические динуклеотидные агонисты sting для лечения рака
WO2018118664A1 (en) * 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
US11033635B2 (en) 2019-07-19 2021-06-15 Immunesensor Therapeutics, Inc. Antibody-STING agonist conjugates and their use in immunotherapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522914A (ja) 2015-08-13 2018-08-16 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Stingアゴニストとしての環状ジヌクレオチド化合物
JP2019509339A (ja) 2016-03-18 2019-04-04 イミューン センサー リミテッド ライアビリティ カンパニー 環状ジヌクレオチド化合物および使用方法
WO2018200812A1 (en) 2017-04-28 2018-11-01 Novartis Ag Antibody conjugates comprising sting agonist
WO2019129880A1 (en) 2017-12-29 2019-07-04 Invivogen Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction

Also Published As

Publication number Publication date
IL289866A (en) 2022-03-01
TWI877186B (zh) 2025-03-21
US12311030B2 (en) 2025-05-27
JP2022541517A (ja) 2022-09-26
WO2021016204A1 (en) 2021-01-28
MX2022000815A (es) 2022-05-03
TW202116358A (zh) 2021-05-01
US20210015941A1 (en) 2021-01-21
KR20220054794A (ko) 2022-05-03
BR112022000854A2 (pt) 2022-03-08
CN114786729A (zh) 2022-07-22
US20210290774A1 (en) 2021-09-23
CN114786729B (zh) 2023-12-19
ZA202201988B (en) 2023-10-25
US11033635B2 (en) 2021-06-15
US11213592B2 (en) 2022-01-04
CA3147890A1 (en) 2021-01-28
EP3999118A1 (en) 2022-05-25
CN117838878A (zh) 2024-04-09
AU2020315802A1 (en) 2022-02-24
US20220105198A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
TWI877186B (zh) 抗體-干擾素基因刺激蛋白(sting)促效劑結合物及其於免疫療法之用途
KR20230008723A (ko) 전하 변이체 링커
EP4115909A1 (en) Antibody-drug conjugate including novel cyclic dinucleotide derivative
JP7335957B2 (ja) 抗体-alk5阻害剤コンジュゲートおよびその使用
JP6957629B2 (ja) 非線状自壊性リンカーおよびそのコンジュゲート
WO2022163846A1 (ja) 抗体-免疫賦活化剤コンジュゲートの新規製造方法
TW202434307A (zh) 抗體偶聯藥物及其用途
CN120267848A (zh) 一种抗体偶联药物及其用途
JP2022548451A (ja) 抗体-alk5阻害剤コンジュゲートおよびその使用
RU2826228C2 (ru) Конъюгаты антитело-sting агонист и их применение в иммунотерапии
HK40076430A (en) Antibody-sting agonist conjugates and their use in immunotherapy
HK40076430B (en) Antibody-sting agonist conjugates and their use in immunotherapy
JP7861240B1 (ja) タンパク質チロシンキナーゼ7抗体及び抗体-薬物コンジュゲート
HK40118815A (en) Antibody-drug conjugate and use thereof
WO2025232773A1 (zh) 药物组合及其用途
KR20250135788A (ko) 세포독성 화합물
HK40130783A (en) Pharmaceutical combination and use thereof
HK40086596A (en) Antibody-drug conjugate including novel cyclic dinucleotide derivative

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230718

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240919

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241010

R150 Certificate of patent or registration of utility model

Ref document number: 7576779

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150